Puma Biotechnology, Inc. (PBYI): Net Income

Annual figures by period end, from SEC filings.

$31.11M

Year ended 2025-12-31

$26.72M

Trailing 12 months to 2026-06-30

n/m

3-year compound annual growth

2011-12-31 Net Income (USD) 2025-12-31

Period ended	Net Income	Change YoY	Source filing
2025-12-31	$31.11M	+2.8%	2026-02-26, From 2025-01-01
2024-12-31	$30.28M	+40.2%	2026-02-26, From 2024-01-01
2023-12-31	$21.59M	n/m	2026-02-26, From 2023-01-01
2022-12-31	$2.0K	n/m	2025-02-27, From 2022-01-01
2021-12-31	-$29.13M	n/m	2024-02-29, From 2021-01-01
2020-12-31	-$59.99M	n/m	2023-03-02, From 2020-01-01
2019-12-31	-$75.59M	n/m	2022-03-03, From 2019-01-01
2018-12-31	-$113.58M	n/m	2021-03-01, From 2018-01-01
2017-12-31	-$291.95M	n/m	2020-02-28, From 2017-01-01
2016-12-31	-$276.01M	n/m	2019-03-01, From 2016-01-01
2015-12-31	-$239.28M	n/m	2018-03-09, From 2015-01-01
2014-12-31	-$141.97M	n/m	2017-03-01, From 2014-01-01
2013-12-31	-$54.66M	n/m	2016-02-29, From 2013-01-01
2012-12-31	-$74.35M	n/m	2015-03-02, From 2012-01-01
2011-12-31	-$10.23M	n/a	2014-03-03, From 2011-01-01

Net Income at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Net Income	Change YoY
Puma Biotechnology, Inc. (PBYI)	2025-12-31	$31.11M	+2.8%
Anaptysbio, Inc (ANAB)	2025-12-31	-$13.23M	n/m
Akebia Therapeutics, Inc. (AKBA)	2025-12-31	-$5.34M	n/m
IDEAYA Biosciences, Inc. (IDYA)	2025-12-31	-$113.70M	n/m
Vanda Pharmaceuticals Inc. (VNDA)	2025-12-31	-$220.47M	n/m
Keros Therapeutics, Inc. (KROS)	2025-12-31	$87.01M	n/m
Amarin Corp PLC (AMRN)	2025-12-31	-$38.80M	n/m
Arcus Biosciences, Inc. (RCUS)	2025-12-31	-$353.00M	n/m
Schrodinger, Inc. (SDGR)	2025-12-31	-$103.27M	n/m

Compare PBYI, ANAB, AKBA, IDYA side by side · Screen every company in Pharmaceutical Preparations ↗